English



A Retrospective Multi-Centre Study on the Spiral Implant

Benny Karmon DMD¹, Jerry Kohen DMD², Ariel Lor DMD³, Yiftach Gratciany DMD⁴, Zvi Laster DMD⁵, Gideon Hallel DMD MPA⁶, Tsvia Karmon

A poster presented at the World conference 2007, Las Vegas, Nevada, USA ¹Petach Tikva, Israel, ²Holon, Israel, ³Tel Aviv, Israel, ⁴Petach Tikva, Israel, ⁵Kinneret, Jordan Valley, Israel, ⁶Tel Aviv, Israel

A Retrospective Multi-Centre Study on the Spiral Implant

Benny Karmon DMD, Jerry Kohen DMD, Ariel Lor DMD, Yiftach Gratciany DMD, Tsvi Laster DMD, Gideon Hallel DMD MPA, Tsvia Karmon

Purpose

To assess the survival rate of the SPIRAL implant with its special advanced design, (Alpha-Bio Tec, Petach-Tikva, Israel) in regular and complicated cases.

Materials and Methods

Consecutively placed SPIRAL implants in six centers were retrospectively followed-up according to a stated protocol. Patient history data and information from the performed treatment were computerized in a database. Failures types and causes were also registered.

The advanced SPIRAL implant design (Fig. 1) incorporates several features including:

Excellent primary stabilization (Fig. 2)

Self-condensing, self-tapping and self-drilling (Fig. 3). Other features allow placement in narrow osteotomies and controlled direction of the insertion path (Fig. 4).

Fig. 1. The advanced SPIRAL implant for demanding situations.



Figures 2 A-D: Achieving primary stability to 50 N/cm with only 1 mm of bone.





Fig. 2A









Fig. 2C



Figures 3 A-C: Self drilling, self tapping.






Fig. 3C

In Figures 3A-C, the drilling was 6 mm length and afterwards 3 SPIRAL implants of 10 mm length were inserted, close to the inferior alveolar nerve.

A total of 648 implants were placed in 251 patients; 362 implants were placed in the maxilla and 286 implants in the mandible. 55% of the implants were placed in the anterior and 45% in the posterior regions of the jaws (Fig. 5). Implant diameters of 3.75, 4.2 and 5.0 mm were used in 53.1, 30.1, 16.7 % of the sites, respectively and 1 implant of 6 mm width. The 13 mm long implant was the most frequently used with 274 implants followed by the 10 mm with 145 implants placed, 11.5 mm with 130 implants placed, 16 mm with 99 implants placed (Table 1).

The surgical procedure included; delayed loading with a onestage procedure and immediately and early loaded implants 36.4% (Fig. 6). Most of the restorations are cemented bridges 81.6% (Fig. 7). Both healed and extraction sites were included. Previous augmentation procedures had been performed for 2.3% of the implant sites, 24.1% of the sited were augmented at the time of implant placement, 12.5% more of the implants were inserted in augmented maxillary sinuses (Fig. 8). The current follow-up period range from 12 to 48 months (meantime 27.4 months) following implant insertion.

Figures 4 A-C: Changing the direction during the insertion.



Fig. 4A



Fig. 4B



Figures 4 A-C demonstrate immediate implantation using the capability of the SPIRAL implant to start the insertion in a first angle inside the palatal wall and afterwards to change the direction to the desired position and angle.

Fig. 4C





Fig. 5: Implant distribution according to implant Location





	10 mm	11.5 mm	13 mm	16 mm	Total
Ø 3.75 mm	77	54	153	60	344
Ø 4.2 mm	35	51	81	28	195
Ø 5 mm	33	25	39	11	108
Ø 6 mm	0	0	1	0	1
Total	145	130	274	99	648


Fig. 6: Implant distribution according to loading mode











Follow up

Figures 9 A-B: Follow up of 4 years with "platform switching".





Figures 9A-B demonstrate one case of 4 SPIRAL implants in the right posterior maxilla, with "platform switching". After 4 years of follow-up, minimal or no apparent bone resorption.

Results

Eleven implants (1.7%) have failed, 7 of them within the first month following placement. Cumulative survival rate is presented in Table 2.

Table 2. Life table analysis and 4-year success data for 648 implants

Interval (years)	No of implants	Failure	CSR%			
1	648	9	98.9			
2	625	1	98.5			
3	358	1	98.3			
4	110	0	98.3			
CSR – Cumulative Survival Rate						

Conclusion

This initial report demonstrates a survival rate of 98.3% after 4 years follow-up of the advanced SPIRAL implant. This high survival rate, which is similar to values reported in other studies, was achieved although 76.1% of the implants were inserted in very demanding situations like immediate implantation 31.8%, immediate and early loading (up to 14 days from implantation) 36.4%, implanting together with augmentation 24.1% and simultaneously with sinus lift procedures 11.7%.

References

- 1. Albrektsson T. A multicenter report on osseointegrated oral implants. J. Prosthet. Dent. 1988;60:75-84
- Adell R, Eriksson B, Lekholm U, Branemark P-I, Jemt T. a long term follow-up study of osseointegrated implants in the treatment of tottaly edentulous jaws. Int. J. Oral Maxillofac. Implants 1990;5:347-559
- Engquist B,Bergendal T, KallusT, Linden U. A retrospective multicenter evaluation of osseointegrated implants supporting overdentures. Int. J. Oral Maxillofac. Implants 1988;2:129-134
- Jemt T, Lekholm U, Adell R. Osseointegration implants in the treatment of partially edentulous patients: A preliminary study on 875 consecutively placed fixtures. Int. J. Oral Maxillofac. Implants 1989;4:211-217
- Szmuler-Moncler S, Reingewirtz Y, Weber HP. Bone response to early loading: the effect of surface state. In: Davidovitch Z, Norton LA (eds). Biological Mechanisms of Tooth Movement and Craniofacial Adaptation. Boston: Harvard Society for the Advancement of Orthodontics, 1996: 611-616.
- Szmuler-Moncler S, Salam H, Reingewirtz Y, Dubruille JH. Timing of loading and effect of micro-motion on bone-implant interface: a review of experimental literature. J. Biomed. Mater. Res. 1998; 43: 192-203.
- Esposito M, Hirsch J-M, Lekholm U, Thomson P. Biological factors contributing to failures of osseointegrated oral implants.(I) Success criteria and epidemiology. Eur. J. oral Sci. 1998;106:527-551
- Roos J, Sennerby L, Albrektsson T. An update on the clinical documentation on currently used bone anchored endosseous oral implants. Dent. Update 1997;24:194-200
- 9. Van Steenberghe D, Quirynen M, Naert I. Survival and success rates with oral endosseos implants. In:Lang NP, Karring T,

Lindhe J. (eds).proceedings of the third European Workshop on periodontology: implant Dentistry Berlin: Quintessenz, 1999;242-254.

- Albrektsson T, Zarb G, Worthington P, et al. The long-term efficacy of currently used dental implants: a review and proposed criteria for success. Int. J. Oral Maxillofac. Implants 1986; 1: 11-25.
- 11. Alpha-Bio LTD. Instruction for use, Surgical Manual.
- Brocard D, Barthet P, Baysse E, Duffort FJ, Eller P, Justumus P, Marin P, Oscaby F, Simonet T, A Multicenter Report on 1,022 Consecutively Placed ITI Implants: A 7-Year Longitudinal Study Int. J. Oral Maxillofac. Implants 2000;15:691–700
- Bahat O., Branemark System Implants in the Posterior Maxilla: Clinical Study of 660 Implants Followed for 5 to 12 Years Int. J. Oral Maxillofac. Implants 2000;15:646–653
- Branemark PI, Hansson BO, Adell R, et al. Osseointegrated implants in the treatment of the edentulous jaw. Experience from a 10-year period. Scan. J. Plast. Reconstr. Surg. 1977; 11 (suppl 16): 1-132.
- Sullivan DY, Sherwood RL, Porter SS. Long-term performance of OSSEOTITE® implants: a 6-year follow-up. Compendium 2002; 22(4): 326-333.
- Friberg B, Jemt T, Lekholm U. Early failures in 4641 consecutively placed Branemark dental implants: a study from stage I surgery to the connection of completed prostheses. Int. J. Oral Maxillofac. Implants 1991; 6: 142-146.
- Cooper L, Felton DA, Kugelberg CF. A multicenter 12-month evaluation of single-tooth implants restored 3 weeks after 1-stage surgery. Int. J. Oral Maxillofac. Implants 2001; 16: 182-192.
- Schwartz-Arad D., Kidron N., Dolev E. A long-term study of implants supporting overdentures as a model for implant success Journal of Periodontology Vol. 76 (pp. 1431-1435) 2005



www.alpha-bio.net

Alpha-Bio Tec Ltd.

7 Hatnufa St. P.O.B 3936 Kiryat Arye, Petach Tikva 49510, Israel Israel T+972-3-9291000 F+972-3-9235055 sales@alpha-bio.net International T+972-3-9291055 F+972-3-9291010 export@alpha-bio.net EC REP MEDES LIMITED

5 Beaumont Gate, Shenley Hill, Radlett, Herts WD7 7AR. England Tel / Fax: +44 1923859810